Pub Date : 2024-02-07DOI: 10.1016/j.imr.2024.101022
Libin Jia , Michelle Beidelschies , Joel M. Evans , Richard C. Niemtzow , Songxuan Zhou Niemtzow , Jeffery A. Dusek , Yufang Lin , Charles Wu , Yi-Chang Su , C. Jason Wang , Chien-Yu Lin , Peristiwan Ridha Widhi Astana , Danang Ardiyanto , Rusmiyati Hardjoutomo , Khwanchai Visithanon , Jagravudh Puagkong , Julalak Chokpaisarn , Martha Villar Lopez , Hiroshi Yotsuyanagi , Myeong Soo Lee , Cecilia C. Maramba-Lazarte
This article - Recommendations and Guidelines of Integrative Medicine (IM) for COVID-19 Care - was one of the outcomes from an Asia-Pacific Economic Cooperation (APEC) Project (Integrative Medicine (IM) and COVID -19 Care) during the time between May 2022 and March 2023. With the efforts from care providers, researchers, health policy makers and healthcare administrative leaders among APEC economies, the purpose of this file was to provide comprehensive IM systems for COVID-19 care as recommendations and suggestive guidelines including care methods, tools, procedures, symptom conditions and targets selections, and points need to be considered during care applications. All cited COVID-19 care practices have confirmed their efficacy and usefulness either used alone or combined with conventional medicine. This article provides current useful medical information on IM for COVID-19 care which could benefit APEC economies and world health communities on their healthcare system.
{"title":"Recommendations and guidelines of integrative medicine for COVID-19 care: The APEC project outcome","authors":"Libin Jia , Michelle Beidelschies , Joel M. Evans , Richard C. Niemtzow , Songxuan Zhou Niemtzow , Jeffery A. Dusek , Yufang Lin , Charles Wu , Yi-Chang Su , C. Jason Wang , Chien-Yu Lin , Peristiwan Ridha Widhi Astana , Danang Ardiyanto , Rusmiyati Hardjoutomo , Khwanchai Visithanon , Jagravudh Puagkong , Julalak Chokpaisarn , Martha Villar Lopez , Hiroshi Yotsuyanagi , Myeong Soo Lee , Cecilia C. Maramba-Lazarte","doi":"10.1016/j.imr.2024.101022","DOIUrl":"https://doi.org/10.1016/j.imr.2024.101022","url":null,"abstract":"<div><p>This article - Recommendations and Guidelines of Integrative Medicine (IM) for COVID-19 Care - was one of the outcomes from an Asia-Pacific Economic Cooperation (APEC) Project (Integrative Medicine (IM) and COVID -19 Care) during the time between May 2022 and March 2023. With the efforts from care providers, researchers, health policy makers and healthcare administrative leaders among APEC economies, the purpose of this file was to provide comprehensive IM systems for COVID-19 care as recommendations and suggestive guidelines including care methods, tools, procedures, symptom conditions and targets selections, and points need to be considered during care applications. All cited COVID-19 care practices have confirmed their efficacy and usefulness either used alone or combined with conventional medicine. This article provides current useful medical information on IM for COVID-19 care which could benefit APEC economies and world health communities on their healthcare system.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"13 1","pages":"Article 101022"},"PeriodicalIF":3.4,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422024000027/pdfft?md5=810297852db3200d2ed65099f89cf9a7&pid=1-s2.0-S2213422024000027-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-06DOI: 10.1016/j.imr.2024.101023
Shanze Wang , Chao Yang , Weimei Zeng , Hongfang Tian , Shihao Du , Jiping Zhao
Background
Hashimoto's thyroiditis (HT) has a high incidence rate and unresolved clinical symptoms. Although Hand Yangming Meridian Penetrating Acupuncture has been used to treat thyroid diseases in China, there is no randomized controlled trial (RCT) on HT.
Methods
This exploratory RCT aims to preliminarily evaluate the efficacy, safety, and feasibility of Hand Yangming Meridian Penetrating Acupuncture in the treatment of HT. Included subjects were randomly assigned to the acupuncture group and the waiting treatment group at a ratio of 1:1. Subjects in the acupuncture group received 16 weeks of acupuncture treatment, followed by a 16-week follow-up observation phase. Subjects in the waiting group received thyroxine supplementation for 16 weeks, followed by 16 weeks of compensation treatment. Serum thyroid peroxidase antibody (TPOab) and thyroglobulin antibody (TGab) levels were the main indicators, and Thyroid-Related Patient-Reported Outcome short form (ThyPRO-39), MOS Item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) scores were also recorded.
Results
In total, 58 subjects were included. After 16 weeks of treatment, there was no statistical difference in the changes in TPOab levels between the two groups, but the TGab level in the acupuncture group was significantly lower than in the waiting group (difference: −141.97 [95 % CI: −222.4 to −61.5], P = 0.011). Moreover, the total ThyPRO-39 and SF-36 scores were statistically different between the two groups (PThyPRO-39 < 0.001, PSF-36 = 0.005). There was no statistical difference in HADS between the two groups.
Conclusions
Hand Yangming Meridian Penetrating Acupuncture may be safe and feasible for HT hypothyroidism to improve symptoms and reduce TGab levels.
Trial registration number
This trial was registered at Acupuncture-Moxibustion Clinical Trial Registry: AMCTR-IOR-19000308 (ChiCTR1900026830, https://www.chictr.org.cn/searchprojEN.html).
{"title":"Acupuncture treatment for Hashimoto's thyroiditis: An exploratory randomized controlled trial","authors":"Shanze Wang , Chao Yang , Weimei Zeng , Hongfang Tian , Shihao Du , Jiping Zhao","doi":"10.1016/j.imr.2024.101023","DOIUrl":"10.1016/j.imr.2024.101023","url":null,"abstract":"<div><h3>Background</h3><p>Hashimoto's thyroiditis (HT) has a high incidence rate and unresolved clinical symptoms. Although Hand Yangming Meridian Penetrating Acupuncture has been used to treat thyroid diseases in China, there is no randomized controlled trial (RCT) on HT.</p></div><div><h3>Methods</h3><p>This exploratory RCT aims to preliminarily evaluate the efficacy, safety, and feasibility of Hand Yangming Meridian Penetrating Acupuncture in the treatment of HT. Included subjects were randomly assigned to the acupuncture group and the waiting treatment group at a ratio of 1:1. Subjects in the acupuncture group received 16 weeks of acupuncture treatment, followed by a 16-week follow-up observation phase. Subjects in the waiting group received thyroxine supplementation for 16 weeks, followed by 16 weeks of compensation treatment. Serum thyroid peroxidase antibody (TPOab) and thyroglobulin antibody (TGab) levels were the main indicators, and Thyroid-Related Patient-Reported Outcome short form (ThyPRO-39), MOS Item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) scores were also recorded.</p></div><div><h3>Results</h3><p>In total, 58 subjects were included. After 16 weeks of treatment, there was no statistical difference in the changes in TPOab levels between the two groups, but the TGab level in the acupuncture group was significantly lower than in the waiting group (difference: −141.97 [95 % CI: −222.4 to −61.5]<em>, P</em> = 0.011). Moreover, the total ThyPRO-39 and SF-36 scores were statistically different between the two groups (<em>P</em><sub>ThyPRO-39</sub> < 0.001, <em>P</em><sub>SF-36</sub> = 0.005). There was no statistical difference in HADS between the two groups.</p></div><div><h3>Conclusions</h3><p>Hand Yangming Meridian Penetrating Acupuncture may be safe and feasible for HT hypothyroidism to improve symptoms and reduce TGab levels.</p></div><div><h3>Trial registration number</h3><p>This trial was registered at Acupuncture-Moxibustion Clinical Trial Registry: AMCTR-IOR-19000308 (ChiCTR1900026830, <span>https://www.chictr.org.cn/searchprojEN.html</span><svg><path></path></svg>).</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"13 1","pages":"Article 101023"},"PeriodicalIF":3.4,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422024000039/pdfft?md5=46d85862d2dae13130ef55fe03b3b5ba&pid=1-s2.0-S2213422024000039-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139754365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-20DOI: 10.1016/j.imr.2024.101021
Xue-Zhou Wang , Cun-Zhi Liu , Li-Qiong Wang , Zhi-Cheng Qu , Ying Cao , Shi-Yan Yan , Jing-Wen Yang , Jian-Feng Tu
Background
The integration of acupuncture with intramuscular injection of diclofenac sodium can expedite the onset of analgesia in treating acute renal colic caused by urolithiasis. However, it remains unclear whether acupuncture can accelerate pain relief constantly until complete remission. This study aimed to explore the extent to which acupuncture can expedite the onset time of response or complete pain relief in treating acute renal colic, and the predictive value of patient characteristics for treatment efficacy.
Methods
This secondary analysis utilized data from a prior randomized controlled trial. Eighty patients with acute renal colic were randomly assigned 1:1 to the acupuncture group or the sham acupuncture group. After intramuscular injection of diclofenac sodium, acupuncture or sham acupuncture was delivered to patients. The outcomes included time to response (at least a 50 % reduction in pain) and complete pain relief. Between-group comparison under the 2 events was estimated by Kaplan-Meier methodology. Subgroup analysis was performed utilizing the Cox proportional hazards model.
Results
The median response time and complete pain relief time in the acupuncture group were lower than those in the sham acupuncture group (5 vs 30 min, Log Rank P < 0.001; 20 min vs not observed, Log Rank P < 0.001, respectively). Hazard Ratios (HRs) for response across all subgroups favored the acupuncture group. All HRs for complete pain relief favored acupuncture, expect large stone and moderate pain at baseline. No interaction was found in either event.
Conclusion
Acupuncture can accelerate the response time and complete pain relief time for patients with acute renal colic, with the efficacy universally.
Trial registration
This study has been registered at Chinese Clinical Trial Registry: ChiCTR1900025202.
背景 在治疗由尿路结石引起的急性肾绞痛时,针灸与肌肉注射双氯芬酸钠的结合可加快镇痛的开始。然而,针灸是否能持续加速疼痛缓解直至完全缓解仍不清楚。本研究旨在探讨针灸在治疗急性肾绞痛时能在多大程度上加快起效时间或完全缓解疼痛,以及患者特征对疗效的预测价值。80 名急性肾绞痛患者按 1:1 随机分配到针灸组或假针灸组。肌肉注射双氯芬酸钠后,对患者进行针灸或假针灸。结果包括反应时间(疼痛至少减轻 50%)和疼痛完全缓解。采用 Kaplan-Meier 方法估算 2 个事件下的组间比较。结果针灸组的反应时间和疼痛完全缓解时间低于假针灸组(分别为 5 分钟 vs 30 分钟,Log Rank P < 0.001;20 分钟 vs 未观察到,Log Rank P < 0.001)。所有分组的反应危险比(HRs)均倾向于针灸组。所有完全缓解疼痛的危险比都倾向于针灸组,预计大结石和基线中度疼痛。结论针灸可加快急性肾绞痛患者的反应时间和完全缓解疼痛的时间,疗效普遍。
{"title":"Acupuncture for response and complete pain relief time of acute renal colic: Secondary analysis of a randomized controlled trial","authors":"Xue-Zhou Wang , Cun-Zhi Liu , Li-Qiong Wang , Zhi-Cheng Qu , Ying Cao , Shi-Yan Yan , Jing-Wen Yang , Jian-Feng Tu","doi":"10.1016/j.imr.2024.101021","DOIUrl":"10.1016/j.imr.2024.101021","url":null,"abstract":"<div><h3>Background</h3><p>The integration of acupuncture with intramuscular injection of diclofenac sodium can expedite the onset of analgesia in treating acute renal colic caused by urolithiasis. However, it remains unclear whether acupuncture can accelerate pain relief constantly until complete remission. This study aimed to explore the extent to which acupuncture can expedite the onset time of response or complete pain relief in treating acute renal colic, and the predictive value of patient characteristics for treatment efficacy.</p></div><div><h3>Methods</h3><p>This secondary analysis utilized data from a prior randomized controlled trial. Eighty patients with acute renal colic were randomly assigned 1:1 to the acupuncture group or the sham acupuncture group. After intramuscular injection of diclofenac sodium, acupuncture or sham acupuncture was delivered to patients. The outcomes included time to response (at least a 50 % reduction in pain) and complete pain relief. Between-group comparison under the 2 events was estimated by Kaplan-Meier methodology. Subgroup analysis was performed utilizing the Cox proportional hazards model.</p></div><div><h3>Results</h3><p>The median response time and complete pain relief time in the acupuncture group were lower than those in the sham acupuncture group (5 vs 30 min, Log Rank <em>P</em> < 0.001; 20 min vs not observed, Log Rank <em>P</em> < 0.001, respectively). Hazard Ratios (HRs) for response across all subgroups favored the acupuncture group. All HRs for complete pain relief favored acupuncture, expect large stone and moderate pain at baseline. No interaction was found in either event.</p></div><div><h3>Conclusion</h3><p>Acupuncture can accelerate the response time and complete pain relief time for patients with acute renal colic, with the efficacy universally.</p></div><div><h3>Trial registration</h3><p>This study has been registered at Chinese Clinical Trial Registry: ChiCTR1900025202.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"13 1","pages":"Article 101021"},"PeriodicalIF":3.4,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422024000015/pdfft?md5=ee00c056134e72095dbd3da8043d8b0c&pid=1-s2.0-S2213422024000015-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139507269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-24DOI: 10.1016/j.imr.2023.101020
Haeun Kim , Dong-Woo Lee , Jae-Kwan Hwang
Background
Cancer cachexia—characterized by anorexia, body weight loss, skeletal muscle atrophy, and fat loss—affects nearly 80% of cancer patients and accounts for 20% of cancer deaths. Curcuma xanthorrhiza, known as Java turmeric, and its active compound xanthorrhizol (XAN) exhibit anticancer, anti-inflammatory, and antioxidant properties. However, the ameliorative effects of C. xanthorrhiza extract (CXE) and XAN on cancer-associated adipose atrophy remain unexplored. This study aimed to evaluate the therapeutic effects of CXE and XAN on cancer cachexia-induced adipose tissue wasting in CT26 tumor-bearing mice.
Methods
CT26 cells were injected subcutaneously into the right flank of BALB/c mice to establish a cancer cachexia model. To evaluate the inhibitory effects of CXE and XAN on cancer cachexia, 50 and 100 mg/kg CXE and 15 mg/kg XAN were administered orally every day for 1 week.
Results
CXE and XAN administration significantly attenuated the loss of body weight and epidydimal fat mass by cancer cachexia. In epididymal adipose tissues, administration of CXE or XAN inhibited white adipose tissue browning by repressing expression of the thermogenic genes. Simultaneously, CXE or XAN attenuated fat catabolism through the downregulation of lipolytic genes. The administration of CXE or XAN induced the expression of genes associated with adipogenesis and lipogenesis-related genes. Moreover, CXE or XAN treatment was associated with maintaining metabolic homeostasis; regulating the expression of adipokines and AMP-activated protein kinase (AMPK).
Conclusions
CXE and XAN mitigate cancer-induced adipose tissue atrophy, primarily by modulating lipid metabolism and WAT browning, indicating their therapeutic potential for cachectic cancer patients.
背景癌症恶病质以厌食、体重下降、骨骼肌萎缩和脂肪减少为特征,影响着近 80% 的癌症患者,占癌症死亡人数的 20%。莪术(又名爪哇姜黄)及其活性化合物黄皮酚(XAN)具有抗癌、抗炎和抗氧化特性。然而,黄柏提取物(CXE)和黄柏酚(XAN)对癌症相关性脂肪萎缩的改善作用仍有待探索。本研究旨在评估 CXE 和 XAN 对 CT26 肿瘤小鼠因癌症恶病质引起的脂肪组织萎缩的治疗作用。为了评估 CXE 和 XAN 对癌症恶病质的抑制作用,小鼠每天口服 50 和 100 mg/kg CXE 和 15 mg/kg XAN,持续 1 周。在附睾脂肪组织中,服用 CXE 或 XAN 可抑制生热基因的表达,从而抑制白色脂肪组织的褐变。同时,CXE 或 XAN 通过下调脂肪分解基因,抑制脂肪分解。服用 CXE 或 XAN 会诱导脂肪生成相关基因和脂肪生成相关基因的表达。结论CXE和XAN主要通过调节脂质代谢和WAT棕色化来缓解癌症诱导的脂肪组织萎缩,这表明它们对恶性肿瘤患者具有治疗潜力。
{"title":"Curcuma xanthorrhiza extract and xanthorrhizol ameliorate cancer-induced adipose wasting in CT26-bearing mice by regulating lipid metabolism and adipose tissue browning","authors":"Haeun Kim , Dong-Woo Lee , Jae-Kwan Hwang","doi":"10.1016/j.imr.2023.101020","DOIUrl":"10.1016/j.imr.2023.101020","url":null,"abstract":"<div><h3>Background</h3><p>Cancer cachexia—characterized by anorexia, body weight loss, skeletal muscle atrophy, and fat loss—affects nearly 80% of cancer patients and accounts for 20% of cancer deaths. <em>Curcuma xanthorrhiza</em>, known as Java turmeric, and its active compound xanthorrhizol (XAN) exhibit anticancer, anti-inflammatory, and antioxidant properties. However, the ameliorative effects of <em>C. xanthorrhiza</em> extract (CXE) and XAN on cancer-associated adipose atrophy remain unexplored. This study aimed to evaluate the therapeutic effects of CXE and XAN on cancer cachexia-induced adipose tissue wasting in CT26 tumor-bearing mice.</p></div><div><h3>Methods</h3><p>CT26 cells were injected subcutaneously into the right flank of BALB/c mice to establish a cancer cachexia model. To evaluate the inhibitory effects of CXE and XAN on cancer cachexia, 50 and 100 mg/kg CXE and 15 mg/kg XAN were administered orally every day for 1 week.</p></div><div><h3>Results</h3><p>CXE and XAN administration significantly attenuated the loss of body weight and epidydimal fat mass by cancer cachexia. In epididymal adipose tissues, administration of CXE or XAN inhibited white adipose tissue browning by repressing expression of the thermogenic genes. Simultaneously, CXE or XAN attenuated fat catabolism through the downregulation of lipolytic genes. The administration of CXE or XAN induced the expression of genes associated with adipogenesis and lipogenesis-related genes. Moreover, CXE or XAN treatment was associated with maintaining metabolic homeostasis; regulating the expression of adipokines and AMP-activated protein kinase (AMPK).</p></div><div><h3>Conclusions</h3><p>CXE and XAN mitigate cancer-induced adipose tissue atrophy, primarily by modulating lipid metabolism and WAT browning, indicating their therapeutic potential for cachectic cancer patients.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"13 1","pages":"Article 101020"},"PeriodicalIF":3.4,"publicationDate":"2023-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000999/pdfft?md5=45e7aae2ce23721f60bbb95812194cda&pid=1-s2.0-S2213422023000999-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139036846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-19DOI: 10.1016/j.imr.2023.101019
Zhe Chen , Dong Zhang , Chunxiang Liu , Hui Wang , Xinyao Jin , Fengwen Yang , Junhua Zhang
Background
With the development of traditional Chinese medicine (TCM) syndrome knowledge accumulation and artificial intelligence (AI), this study proposes a holistic TCM syndrome differentiation model for the classification prediction of multiple TCM syndromes based on deep learning and accelerates the construction of modern foundational TCM equipment.
Methods
We searched publicly available TCM guidelines and textbooks for expert knowledge and validated these sources using ten-fold cross-validation. Based on the BERT and CNN models, with the classification constraints from TCM holistic syndrome differentiation, the TCM-BERT-CNN model was constructed, which completes the end-to-end TCM holistic syndrome text classification task through symptom input and syndrome output. We assessed the performance of the model using precision, recall, and F1 scores as evaluation metrics.
Results
The TCM-BERT-CNN model had a higher precision (0.926), recall (0.9238), and F1 score (0.9247) than the BERT, TextCNN, LSTM RNN, and LSTM ATTENTION models and achieved superior results in model performance and predictive classification of most TCM syndromes. Symptom feature visualization demonstrated that the TCM-BERT-CNN model can effectively identify the correlation and characteristics of symptoms in different syndromes with a strong correlation, which conforms to the diagnostic characteristics of TCM syndromes.
Conclusions
The TCM-BERT-CNN model proposed in this study is in accordance with the TCM diagnostic characteristics of holistic syndrome differentiation and can effectively complete diagnostic prediction tasks for various TCM syndromes. The results of this study provide new insights into the development of deep learning models for holistic syndrome differentiation in TCM.
{"title":"Traditional Chinese medicine diagnostic prediction model for holistic syndrome differentiation based on deep learning","authors":"Zhe Chen , Dong Zhang , Chunxiang Liu , Hui Wang , Xinyao Jin , Fengwen Yang , Junhua Zhang","doi":"10.1016/j.imr.2023.101019","DOIUrl":"10.1016/j.imr.2023.101019","url":null,"abstract":"<div><h3>Background</h3><p>With the development of traditional Chinese medicine (TCM) syndrome knowledge accumulation and artificial intelligence (AI), this study proposes a holistic TCM syndrome differentiation model for the classification prediction of multiple TCM syndromes based on deep learning and accelerates the construction of modern foundational TCM equipment.</p></div><div><h3>Methods</h3><p>We searched publicly available TCM guidelines and textbooks for expert knowledge and validated these sources using ten-fold cross-validation. Based on the BERT and CNN models, with the classification constraints from TCM holistic syndrome differentiation, the TCM-BERT-CNN model was constructed, which completes the end-to-end TCM holistic syndrome text classification task through symptom input and syndrome output. We assessed the performance of the model using precision, recall, and F1 scores as evaluation metrics.</p></div><div><h3>Results</h3><p>The TCM-BERT-CNN model had a higher precision (0.926), recall (0.9238), and F1 score (0.9247) than the BERT, TextCNN, LSTM RNN, and LSTM ATTENTION models and achieved superior results in model performance and predictive classification of most TCM syndromes. Symptom feature visualization demonstrated that the TCM-BERT-CNN model can effectively identify the correlation and characteristics of symptoms in different syndromes with a strong correlation, which conforms to the diagnostic characteristics of TCM syndromes.</p></div><div><h3>Conclusions</h3><p>The TCM-BERT-CNN model proposed in this study is in accordance with the TCM diagnostic characteristics of holistic syndrome differentiation and can effectively complete diagnostic prediction tasks for various TCM syndromes. The results of this study provide new insights into the development of deep learning models for holistic syndrome differentiation in TCM.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"13 1","pages":"Article 101019"},"PeriodicalIF":3.4,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000987/pdfft?md5=99cd836599379ae327efed4c3301b406&pid=1-s2.0-S2213422023000987-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138745678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1016/j.imr.2023.101014
Michael Borenstein
In any meta-analysis it is important to report not only the mean effect size but also how the effect size varies across studies. A treatment that has a moderate clinical impact in all studies is very different than a treatment where the impact is moderate on average, but in some studies is large and in others is trivial (or even harmful). A treatment that has no impact in any studies is very different than a treatment that has no impact on average because it is helpful in some studies but harmful in others. The majority of meta-analyses use the I-squared index to quantify heterogeneity. While this practice is common it is nevertheless incorrect. I-squared does not tell us how much the effect size varies (except when I-squared is zero percent). The statistic that does convey this information is the prediction interval. It allows us to report, for example, that a treatment has a clinically trivial or moderate effect in roughly 10 % of studies, a large effect in roughly 50 %, and a very large effect in roughly 40 %. This is the information that researchers or clinicians have in mind when they ask about heterogeneity. It is the information that researchers believe (incorrectly) is provided by I-squared.
{"title":"How to understand and report heterogeneity in a meta-analysis: The difference between I-squared and prediction intervals","authors":"Michael Borenstein","doi":"10.1016/j.imr.2023.101014","DOIUrl":"10.1016/j.imr.2023.101014","url":null,"abstract":"<div><p>In any meta-analysis it is important to report not only the mean effect size but also how the effect size varies across studies. A treatment that has a moderate clinical impact in all studies is very different than a treatment where the impact is moderate on average, but in some studies is large and in others is trivial (or even harmful). A treatment that has no impact in any studies is very different than a treatment that has no impact on average because it is helpful in some studies but harmful in others. The majority of meta-analyses use the I-squared index to quantify heterogeneity. While this practice is common it is nevertheless incorrect. I-squared does not tell us how much the effect size varies (except when I-squared is zero percent). The statistic that does convey this information is the prediction interval. It allows us to report, for example, that a treatment has a clinically trivial or moderate effect in roughly 10 % of studies, a large effect in roughly 50 %, and a very large effect in roughly 40 %. This is the information that researchers or clinicians have in mind when they ask about heterogeneity. It is the information that researchers believe (incorrectly) is provided by I-squared.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"12 4","pages":"Article 101014"},"PeriodicalIF":3.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000938/pdfft?md5=e4a81bd65e0c133ffa3fa698f4f8c8a9&pid=1-s2.0-S2213422023000938-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-15DOI: 10.1016/j.imr.2023.101007
You Mee Ahn , Hye Yoom Kim , Dae Gill Kang , Kyung Woo Cho , Ho Sub Lee
Background
Herbal medicine Oryeongsan (ORS), also known as Wulingsan in Chinesehas been used for the treatment of impaired body fluid balance. However, the mechanisms involved are not clearly defined. The purpose of the present study was to identify the actions of ORS on the renal excretory function and blood pressure (BP) and to define the mechanisms involved in association with renin-angiotensin system (RAS) and natriuretic peptide system (NPS) in spontaneously hypertensive rats (SHR), an animal model of human essential hypertension.
Methods
Changes in urine volume (UV), excretion of electrolytes including Na+ (urinary excretion of Na+ (UNaV)) were measured. RT-PCR was performed to trace the changes in expression of RAS, NPS and sodium (Na+)-hydrogen (H+) exchanger 3 (NHE3) in the renal cortex.
Results
In the SHR treated with vehicle (SHR-V) group, UV and UNaV were suppressed and the Na+ balance was maintained at the higher levels leading to an increase in BP compared to WKY-V group. These were accompanied by an increase in NHE3 expression with an accentuation of angiotensin I converting enzyme-angiotensin II type 1 (ACE-AT1) receptor and concurrent suppression of angiotensin II type 2 (AT2) receptor/ACE2-Mas receptor expression in the renal cortex. Chronic treatment with ORS increased UV and UNaV, and decreased the Na+ and water balance with a decrease in BP in the ORS-treated SHR-ORS group compared to SHR-V. These were accompanied by a decrease in NHE3 expression with a suppression of ACE-AT1 receptor and concurrent accentuation of AT2/ACE2-Mas receptor.
Conclusion
The present study shows that ORS reduced BP with a decrease in Na+ and water retention by a suppression of NHE3 expression via modulation of RAS and NPS in SHR. The present study provides pharmacological rationale for the treatment of hypertension with ORS in SHR.
{"title":"Herbal medicine (Oryeongsan) for fluid and sodium balance in renal cortex of spontaneously hypertensive rats","authors":"You Mee Ahn , Hye Yoom Kim , Dae Gill Kang , Kyung Woo Cho , Ho Sub Lee","doi":"10.1016/j.imr.2023.101007","DOIUrl":"10.1016/j.imr.2023.101007","url":null,"abstract":"<div><h3>Background</h3><p>Herbal medicine Oryeongsan (ORS), also known as Wulingsan in Chinesehas been used for the treatment of impaired body fluid balance. However, the mechanisms involved are not clearly defined. The purpose of the present study was to identify the actions of ORS on the renal excretory function and blood pressure (BP) and to define the mechanisms involved in association with renin-angiotensin system (RAS) and natriuretic peptide system (NPS) in spontaneously hypertensive rats (SHR), an animal model of human essential hypertension.</p></div><div><h3>Methods</h3><p>Changes in urine volume (UV), excretion of electrolytes including Na<sup>+</sup> (urinary excretion of Na<sup>+</sup> (U<sub>Na</sub>V)) were measured. RT-PCR was performed to trace the changes in expression of RAS, NPS and sodium (Na<sup>+</sup>)-hydrogen (H<sup>+</sup>) exchanger 3 (NHE3) in the renal cortex.</p></div><div><h3>Results</h3><p>In the SHR treated with vehicle (SHR-V) group, UV and U<sub>Na</sub>V were suppressed and the Na<sup>+</sup> balance was maintained at the higher levels leading to an increase in BP compared to WKY-V group. These were accompanied by an increase in NHE3 expression with an accentuation of angiotensin I converting enzyme-angiotensin II type 1 (ACE-AT<sub>1</sub>) receptor and concurrent suppression of angiotensin II type 2 (AT<sub>2</sub>) receptor/ACE2-Mas receptor expression in the renal cortex. Chronic treatment with ORS increased UV and U<sub>Na</sub>V, and decreased the Na<sup>+</sup> and water balance with a decrease in BP in the ORS-treated SHR-ORS group compared to SHR-V. These were accompanied by a decrease in NHE3 expression with a suppression of ACE-AT<sub>1</sub> receptor and concurrent accentuation of AT<sub>2</sub>/ACE2-Mas receptor.</p></div><div><h3>Conclusion</h3><p>The present study shows that ORS reduced BP with a decrease in Na<sup>+</sup> and water retention by a suppression of NHE3 expression via modulation of RAS and NPS in SHR. The present study provides pharmacological rationale for the treatment of hypertension with ORS in SHR.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"13 1","pages":"Article 101007"},"PeriodicalIF":3.4,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000860/pdfft?md5=0c9cd122c13cfac60634d2df0b47ce73&pid=1-s2.0-S2213422023000860-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-15DOI: 10.1016/j.imr.2023.101006
Cong Zhan , Han Byeol Jang , DanBi Ahn , Suchan Chang , Yeonhee Ryu , Hyung Kyu Kim , Bong Hyo Lee , Xiaowei Guan , Yu Fan , Bae Hwan Lee , Hee Young Kim
Background
Our previous studies proved that neurogenic inflammatory spots (or neurogenic spots) have the same physiological features as acupuncture points and that neurogenic spot stimulation generates therapeutic effects in various animal models. However, it is unclear how deeply the neurogenic spots should be stimulated to generate therapeutic effects.
Methods
The effects of acupuncture at various needle depths below the neurogenic spot were examined in a rat immobilization stress-induced hypertension (IMH) model. Electroacupuncture was applied to a neurogenic spot at depths of 1, 2, or 3 mm using a concentric bipolar electrode.
Results
Electrical stimulation of the neurogenic spot at a 3-mm depth most effectively lowered blood pressure compared with controls and stimulation at 1- and 2-mm depths, which was inhibited by pretreatment with a local anesthetic lidocaine. Electrical stimulation of the neurogenic spot or injection of substance P (SP) at a 3-mm depth significantly excited the rostral ventrolateral medulla (rVLM) compared with superficial stimulation. Electrical stimulation applied at a 3-mm depth on neurogenic spots dominantly caused c-fos expression from rVLM and ventrolateral periaqueductal gray (vlPAG) in IMH rats. Pretreatment with resiniferatoxin (RTX) injection into the neurogenic spot to ablate SP or calcitonin gene-related peptide (CGRP) prevented the effects of 3-mm neurogenic spot stimulation on blood pressure in IMH rats. Conversely, artificial injection of SP or CGRP generated anti-hypertensive effects in IMH rats.
Conclusion
Our data suggest that neurogenic spot stimulation at a 3-mm depth generated anti-hypertensive effects through the local release of SP and CGRP and activation of rVLM and vlPAG.
{"title":"Deep electroacupuncture of neurogenic spots attenuates immobilization stress-induced acute hypertension in rats","authors":"Cong Zhan , Han Byeol Jang , DanBi Ahn , Suchan Chang , Yeonhee Ryu , Hyung Kyu Kim , Bong Hyo Lee , Xiaowei Guan , Yu Fan , Bae Hwan Lee , Hee Young Kim","doi":"10.1016/j.imr.2023.101006","DOIUrl":"10.1016/j.imr.2023.101006","url":null,"abstract":"<div><h3>Background</h3><p>Our previous studies proved that neurogenic inflammatory spots (or neurogenic spots) have the same physiological features as acupuncture points and that neurogenic spot stimulation generates therapeutic effects in various animal models. However, it is unclear how deeply the neurogenic spots should be stimulated to generate therapeutic effects.</p></div><div><h3>Methods</h3><p>The effects of acupuncture at various needle depths below the neurogenic spot were examined in a rat immobilization stress-induced hypertension (IMH) model. Electroacupuncture was applied to a neurogenic spot at depths of 1, 2, or 3 mm using a concentric bipolar electrode.</p></div><div><h3>Results</h3><p>Electrical stimulation of the neurogenic spot at a 3-mm depth most effectively lowered blood pressure compared with controls and stimulation at 1- and 2-mm depths, which was inhibited by pretreatment with a local anesthetic lidocaine. Electrical stimulation of the neurogenic spot or injection of substance P (SP) at a 3-mm depth significantly excited the rostral ventrolateral medulla (rVLM) compared with superficial stimulation. Electrical stimulation applied at a 3-mm depth on neurogenic spots dominantly caused c-fos expression from rVLM and ventrolateral periaqueductal gray (vlPAG) in IMH rats. Pretreatment with resiniferatoxin (RTX) injection into the neurogenic spot to ablate SP or calcitonin gene-related peptide (CGRP) prevented the effects of 3-mm neurogenic spot stimulation on blood pressure in IMH rats. Conversely, artificial injection of SP or CGRP generated anti-hypertensive effects in IMH rats.</p></div><div><h3>Conclusion</h3><p>Our data suggest that neurogenic spot stimulation at a 3-mm depth generated anti-hypertensive effects through the local release of SP and CGRP and activation of rVLM and vlPAG.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"13 1","pages":"Article 101006"},"PeriodicalIF":3.4,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000859/pdfft?md5=c21f1979ec1868c76b8ef02365b3c358&pid=1-s2.0-S2213422023000859-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138536286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-28DOI: 10.1016/j.imr.2023.101003
Nora Giese , Ki Kyung Kwon , Mike Armour
Background
Current endometriosis treatments do not always provide symptom relief, with many using complementary approaches. This study examined the effectiveness of acupuncture on pain and quality of life in people with endometriosis.
Methods
Searches were conducted on Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Allied and Complementary Medicine Database (AMED) and Embase (Ovid), Epistemonikos, and Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCOhost) on 20 March 2023. Trials were included if they used penetrating acupuncture. Risk of bias was assessed with Cochrane RoB2 and GRADE for overall evidence certainty. Random-effects meta-analyses were undertaken, using Hedges’ g or mean difference (MD) both with 95 % confidence intervals (CI).
Results
Six studies involving a total of 331 participants were included. Evidence for benefit was found for acupuncture compared to non-specific acupuncture on overall pelvic pain (g = 1.54, 95 % CI 0.92 to 2.16, 3 RCTs, n = 231, low certainty evidence, p<0.001), menstrual pain (g = 1.67, 95 % CI 1.23 to 2.12, 1 RCT, n = 106, moderate certainty evidence, p<0.001), and non-specified pelvic pain (MD -2.77, 95 % CI 2.15 to 3.38, 2 RCTs, n = 125, low certainty evidence, p<0.001), and compared to usual care on menstrual pain (g = 0.9, 95 % CI 0.15 to 1.64, 1 RCT, n = 19, very low certainty evidence, p = 0.02). Most studies reported low rates of adverse events.
Conclusion
Acupuncture treatment for endometriosis demonstrated clinically relevant improvements in pelvic pain and should be considered as a potential treatment intervention.
{"title":"Acupuncture for endometriosis: A systematic review and meta-analysis","authors":"Nora Giese , Ki Kyung Kwon , Mike Armour","doi":"10.1016/j.imr.2023.101003","DOIUrl":"https://doi.org/10.1016/j.imr.2023.101003","url":null,"abstract":"<div><h3>Background</h3><p>Current endometriosis treatments do not always provide symptom relief, with many using complementary approaches. This study examined the effectiveness of acupuncture on pain and quality of life in people with endometriosis.</p></div><div><h3>Methods</h3><p>Searches were conducted on Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Allied and Complementary Medicine Database (AMED) and Embase (Ovid), Epistemonikos, and Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCOhost) on 20 March 2023. Trials were included if they used penetrating acupuncture. Risk of bias was assessed with Cochrane RoB2 and GRADE for overall evidence certainty. Random-effects meta-analyses were undertaken, using Hedges’ g or mean difference (MD) both with 95 % confidence intervals (CI).</p></div><div><h3>Results</h3><p>Six studies involving a total of 331 participants were included. Evidence for benefit was found for acupuncture compared to non-specific acupuncture on overall pelvic pain (<em>g</em> = 1.54, 95 % CI 0.92 to 2.16, 3 RCTs, <em>n</em> = 231, low certainty evidence, <em>p</em><0.001), menstrual pain (<em>g</em> = 1.67, 95 % CI 1.23 to 2.12, 1 RCT, <em>n</em> = 106, moderate certainty evidence, <em>p</em><0.001), and non-specified pelvic pain (MD -2.77, 95 % CI 2.15 to 3.38, 2 RCTs, <em>n</em> = 125, low certainty evidence, <em>p</em><0.001), and compared to usual care on menstrual pain (<em>g</em> = 0.9, 95 % CI 0.15 to 1.64, 1 RCT, <em>n</em> = 19, very low certainty evidence, <em>p</em> = 0.02). Most studies reported low rates of adverse events.</p></div><div><h3>Conclusion</h3><p>Acupuncture treatment for endometriosis demonstrated clinically relevant improvements in pelvic pain and should be considered as a potential treatment intervention.</p></div><div><h3>Study registration</h3><p>PROSPERO ID: CRD42023408700.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"12 4","pages":"Article 101003"},"PeriodicalIF":3.4,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000823/pdfft?md5=7e9447f30969daae3f16f7321e5fa465&pid=1-s2.0-S2213422023000823-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91729242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-28DOI: 10.1016/j.imr.2023.101004
Yun-Ru Chen , Ruo-Tong Zhao , Yi-Fang Xu , Yin-Jie Ma , Shao-Bo Hu , Xue-Hui Wang , Bing-Bing Fan , Yan-Ji Zhou , Yu-Bei Huang , Nicola Robinson , Jian-Ping Liu , Zhao-Lan Liu
Background
Advanced pancreatic cancer (APC) is a fatal disease with limited treatment options. This study aims to evaluate the effectiveness and safety of different Chinese herbal injections (CHIs) as adjuvants for radiotherapy (RT) in APC and compare their treatment potentials using network meta-analysis.
Methods
We systematically searched three English and four Chinese databases for randomized controlled trials (RCTs) from inception to July 25, 2023. The primary outcome was the objective response rate (ORR). Secondary outcomes included Karnofsky performance status (KPS) score, overall survival (OS), and adverse events (AEs). The treatment potentials of different CHIs were ranked using the surface under the cumulative ranking curve (SUCRA). The Cochrane RoB 2 tool and CINeMA were used for quality assessment and evidence grading.
Results
Eighteen RCTs involving 1199 patients were included. Five CHIs were evaluated. Compound Kushen injection (CKI) combined with RT significantly improved ORR compared to RT alone (RR 1.49, 95 % CrI 1.21–1.86). Kanglaite (KLT) plus RT (RR 1.58, 95 % CrI 1.20–2.16) and CKI plus RT (RR 1.49, 95 % CrI 1.16–1.95) were associated with improved KPS score compared to radiation monotherapy, with KLT+RT being the highest rank (SUCRA 72.28 %). Regarding AEs, CKI plus RT was the most favorable in reducing the incidence of leukopenia (SUCRA 90.37 %) and nausea/vomiting (SUCRA 85.79 %).
Conclusions
CKI may be the optimal choice of CHIs to combine with RT for APC as it may improve clinical response, quality of life, and reduce AEs. High-quality trials are necessary to establish a robust body of evidence.
{"title":"Chinese herbal injections in combination with radiotherapy for advanced pancreatic cancer: A systematic review and network meta-analysis","authors":"Yun-Ru Chen , Ruo-Tong Zhao , Yi-Fang Xu , Yin-Jie Ma , Shao-Bo Hu , Xue-Hui Wang , Bing-Bing Fan , Yan-Ji Zhou , Yu-Bei Huang , Nicola Robinson , Jian-Ping Liu , Zhao-Lan Liu","doi":"10.1016/j.imr.2023.101004","DOIUrl":"https://doi.org/10.1016/j.imr.2023.101004","url":null,"abstract":"<div><h3>Background</h3><p>Advanced pancreatic cancer (APC) is a fatal disease with limited treatment options. This study aims to evaluate the effectiveness and safety of different Chinese herbal injections (CHIs) as adjuvants for radiotherapy (RT) in APC and compare their treatment potentials using network meta-analysis.</p></div><div><h3>Methods</h3><p>We systematically searched three English and four Chinese databases for randomized controlled trials (RCTs) from inception to July 25, 2023. The primary outcome was the objective response rate (ORR). Secondary outcomes included Karnofsky performance status (KPS) score, overall survival (OS), and adverse events (AEs). The treatment potentials of different CHIs were ranked using the surface under the cumulative ranking curve (SUCRA). The Cochrane RoB 2 tool and CINeMA were used for quality assessment and evidence grading.</p></div><div><h3>Results</h3><p>Eighteen RCTs involving 1199 patients were included. Five CHIs were evaluated. Compound Kushen injection (CKI) combined with RT significantly improved ORR compared to RT alone (RR 1.49, 95 % CrI 1.21–1.86). Kanglaite (KLT) plus RT (RR 1.58, 95 % CrI 1.20–2.16) and CKI plus RT (RR 1.49, 95 % CrI 1.16–1.95) were associated with improved KPS score compared to radiation monotherapy, with KLT+RT being the highest rank (SUCRA 72.28 %). Regarding AEs, CKI plus RT was the most favorable in reducing the incidence of leukopenia (SUCRA 90.37 %) and nausea/vomiting (SUCRA 85.79 %).</p></div><div><h3>Conclusions</h3><p>CKI may be the optimal choice of CHIs to combine with RT for APC as it may improve clinical response, quality of life, and reduce AEs. High-quality trials are necessary to establish a robust body of evidence.</p></div><div><h3>Protocol registration</h3><p>PROSPERO, CRD42023396828.</p></div>","PeriodicalId":13644,"journal":{"name":"Integrative Medicine Research","volume":"12 4","pages":"Article 101004"},"PeriodicalIF":3.4,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213422023000835/pdfft?md5=c012ec98ecae9827618f6a1754040b40&pid=1-s2.0-S2213422023000835-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92100320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}